Adrian Rawlinson Written by our editorial team | Last reviewed January 15, 2026 Excellent 4.6 /5 Very easy to order - I put in my request, explained my situation, a doctor read it and approved it and my prescription was processed and sent out
Semaglutide (GLP-1 agonist): approximately 15% weight loss at 2.4 mg weekly Tirzepatide (GLP-1 and GIP dual agonist): up to 20.9% weight loss at 15 mg weekly Retatrutide (triple agonist): up to 24.2% weight loss at 12 mg weekly All three share once-weekly subcutaneous injection administration Retatrutide's glucagon receptor activity drives additional energy expenditure Key Takeaways Retatrutide is administered once weekly by subcutaneous injection, with Phase 2 trial doses ranging from 2 mg to 12 mg per week The 12 mg weekly maintenance dose produced the greatest average weight loss of 24.2% over 48 weeks in clinical trials Dosing always begins at a low starting dose (2 mg weekly) and escalates gradually over 16 to 24 weeks to minimise gastrointestinal side effects Retatrutide is not currently approved by the MHRA and is not available as a prescribed medication in the UK as of 2026 For those seeking treatment now, clinically approved weekly injectables such as semaglutide and tirzepatide are available through regulated prescribers When to Seek Professional Advice If you are considering retatrutide or any other injectable weight loss medication, speaking with a qualified prescribing pharmacist or doctor is essential before making any decisions
Research Context and Scientific Interest Researchers investigating Retatrutide frequently examine: GLP-1 receptor signaling pathways GIP receptor biology Glucagon receptor activity Metabolic signaling networks Peptide engineering research Multi-receptor agonist models Cellular communication pathways The compounds triple-receptor profile makes it a unique subject within modern peptide science and receptor signaling investigations
Biotene Gentle Mint toothpaste is designed for this purpose and does not contain sodium lauryl sulfate, a foaming agent in standard toothpastes that can irritate dry oral tissues
The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2
In 1931 he recorded similar results in dogs (Creutzfeldt
